The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate Pharmaceuticals. Dr. Osei Tutu brings valuable regulatory experience in the immune-oncology landscape to the team at Checkmate as they keep their focus on important regulatory milestones for vidutolimod. This hands-on role gives Dr. Osei Tutu responsibility for the development and execution of Checkmate’s global regulatory strategy as the team’s regulatory expert. Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate is investigating their lead candidate, vidutolimod, across multiple tumor types in combination with checkpoint inhibitor immunotherapies in melanoma and non-melanoma skin cancers and head and neck cancer. A growing body of promising clinical data demonstrates its potential to address the unmet need for patients whose cancers are resistant to immunotherapeutic agents. Dr. Osei Tutu joins a team of scientists, physicians, and life sciences entrepreneurs who are dedicated to discovering and developing new approaches to fighting cancer. The Chase Group is proud to partner with Checkmate and contribute to their success as they work to harness the power of the immune system to combat cancer. For more information on partnering with The Chase Group to identify & secure executive leadership for your organization contact moira@chasegroup.com
The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate Pharmaceuticals. Dr. Osei Tutu brings valuable regulatory experience in the immune-oncology landscape to the team at Checkmate as they keep their focus on important regulatory milestones for vidutolimod. This hands-on role gives Dr. Osei Tutu responsibility for the development and execution of Checkmate’s global regulatory strategy as the team’s regulatory expert. Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate is investigating their lead candidate, vidutolimod, across multiple tumor types in combination with checkpoint inhibitor immunotherapies in melanoma and non-melanoma skin cancers and head and neck cancer. A growing body of promising clinical data demonstrates its potential to address the unmet need for patients whose cancers are resistant to immunotherapeutic agents. Dr. Osei Tutu joins a team of scientists, physicians, and life sciences entrepreneurs who are dedicated to discovering and developing new approaches to fighting cancer. The Chase Group is proud to partner with Checkmate and contribute to their success as they work to harness the power of the immune system to combat cancer. For more information on partnering with The Chase Group to identify & secure executive leadership for your organization contact moira@chasegroup.com- Categories: Life Sciences
Ionis Director, Global HEOR, Rare Disease Immunology, Successfully Placed by The Chase Group
Ami Claxton, MS, PhD has joined Ionis Pharmaceuticals, Inc. as Director, Global HEOR Rare Disease Immunology. She will play a critical and significant role as…
Successful Placement at Avidity
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years…
The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on…
The Chase Group Identifies Chief Medical Officer for Arcturus Therapeutics
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer,…
The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…